Stroke remains one of the most common causes of death and disability worldwide. Several preclinical studies demonstrated that the brain can be effectively protected against ischaemic stroke by two seemingly distinct treatments: remote ischaemic conditioning (RIC), involving cycles of ischaemia/reperfusion applied to a peripheral organ or tissue, or by systemic administration of glucagon-like-peptide-1 (GLP-1) receptor (GLP-1R) agonists. The mechanisms underlying RIC- and GLP-1-induced neuroprotection are not completely understood. In this study, we tested the hypothesis that GLP-1 mediates neuroprotection induced by RIC and investigated the effect of GLP-1R activation on cerebral blood vessels, as a potential mechanism of GLP-1-induced prot...
Stroke mortality and morbidity is expected to rise. Despite considerable recent advances within acut...
Stroke is the leading cause of disability in adults in westernized societies and it has an important...
Glucagon-like peptide-1 (GLP-1) is an endogenous insulinotropic peptide secreted from the gastrointe...
Abstract: Stroke remains one of the most common causes of death and disability worldwide. Several pr...
Stroke remains one of the most common causes of death and disability worldwide. Several preclinical ...
International audienceSeveral randomized controlled trials have demonstrated the benefits of glucago...
International audienceSeveral randomized controlled trials have demonstrated the benefits of glucago...
International audienceSeveral randomized controlled trials have demonstrated the benefits of glucago...
International audienceSeveral randomized controlled trials have demonstrated the benefits of glucago...
International audienceSeveral randomized controlled trials have demonstrated the benefits of glucago...
Several randomized controlled trials have demonstrated the benefits of glucagon-like peptide-1 recep...
<div><p>Diabetes is a major risk factor for the development of stroke. Glucagon-like peptide-1 recep...
Background and Purpose: Glucagon-like peptide-1 (GLP-1) receptor activation decreases stroke risk in...
Background and Purpose: Glucagon-like peptide-1 (GLP-1) receptor activation decreases stroke risk in...
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agon...
Stroke mortality and morbidity is expected to rise. Despite considerable recent advances within acut...
Stroke is the leading cause of disability in adults in westernized societies and it has an important...
Glucagon-like peptide-1 (GLP-1) is an endogenous insulinotropic peptide secreted from the gastrointe...
Abstract: Stroke remains one of the most common causes of death and disability worldwide. Several pr...
Stroke remains one of the most common causes of death and disability worldwide. Several preclinical ...
International audienceSeveral randomized controlled trials have demonstrated the benefits of glucago...
International audienceSeveral randomized controlled trials have demonstrated the benefits of glucago...
International audienceSeveral randomized controlled trials have demonstrated the benefits of glucago...
International audienceSeveral randomized controlled trials have demonstrated the benefits of glucago...
International audienceSeveral randomized controlled trials have demonstrated the benefits of glucago...
Several randomized controlled trials have demonstrated the benefits of glucagon-like peptide-1 recep...
<div><p>Diabetes is a major risk factor for the development of stroke. Glucagon-like peptide-1 recep...
Background and Purpose: Glucagon-like peptide-1 (GLP-1) receptor activation decreases stroke risk in...
Background and Purpose: Glucagon-like peptide-1 (GLP-1) receptor activation decreases stroke risk in...
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agon...
Stroke mortality and morbidity is expected to rise. Despite considerable recent advances within acut...
Stroke is the leading cause of disability in adults in westernized societies and it has an important...
Glucagon-like peptide-1 (GLP-1) is an endogenous insulinotropic peptide secreted from the gastrointe...